This is a preview of subscription content, log in via an institution to check access.
References
Ota K, Taguchi T, Kimura K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 1988; 22(4): 333–8
Ikeda E, Kodaira S, Teramoto T, et al. Optimal dosage of UFT + MMC combination chemotherapy for advanced colorectal cancer-phase I/II study of combination chemotherapy of MMC with 2-week intervals and intermittent UFT administration-Study Group of UFTM Therapy for Advanced Colorectal Cancer [in Japanese]. Gan To Kagaku Ryoho 1996; 23: 1291–8
Kusunoki M, Yanagi H, Noda M, et al. The usefulness of pharmacokinetic modulating chemotherapy (UFT plus 5FU) in the treatment of unresectable colorectal carcinomas. Oncol Rep 1999; 6: 547–52
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kato, T. Tegafur/Uracil. Drugs Aging 18, 949 (2001). https://doi.org/10.2165/00002512-200118120-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002512-200118120-00006